Cargando…

Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series

We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 monoclonal antibodies and sphingosine-one-phosphate modulators) and with reduced COVID-19 vaccine response, who had mild-to-moderate symptomatic COVID-19, and were treated with anti-SARS-CoV-2 monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moccia, Marcello, Buonomo, Antonio Riccardo, Scotto, Riccardo, Viceconte, Giulio, Nobile, Mariano, Lanzillo, Roberta, Brescia Morra, Vincenzo, Gentile, Ivan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Clinical Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159779/ https://www.ncbi.nlm.nih.gov/pubmed/35689866 http://dx.doi.org/10.1016/j.jns.2022.120306

Ejemplares similares

Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
por: De Angelis, Marcello, et al.
Publicado: (2020)

COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak
por: Buonomo, Antonio, et al.
Publicado: (2020)

Assessing disability and relapses in multiple sclerosis on tele-neurology
por: Moccia, Marcello, et al.
Publicado: (2020)

Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review
por: De Angelis, Marcello, et al.
Publicado: (2021)

Neuroimaging Correlates of Cognitive Dysfunction in Adults with Multiple Sclerosis
por: Petracca, Maria, et al.
Publicado: (2021)

Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg
por: Capasso, Nicola, et al.
Publicado: (2020)

Prevalence of SARS-CoV-2 antibodies in multiple sclerosis: The hidden part of the iceberg
por: Capasso, Nicola, et al.
Publicado: (2021)

Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015
por: Moccia, Marcello, et al.
Publicado: (2017)

Google Maps Timeline: An open-access digital tool to monitor walking abilities in people with multiple sclerosis
por: Caliendo, Daniele, et al.
Publicado: (2023)

Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2022)

Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2022)

Sample Size for Oxidative Stress and Inflammation When Treating Multiple Sclerosis with Interferon-β1a and Coenzyme Q10
por: Moccia, Marcello, et al.
Publicado: (2019)

Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
por: Moccia, Marcello, et al.
Publicado: (2020)

Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis
por: Carotenuto, Antonio, et al.
Publicado: (2019)

Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data
por: Moccia, Marcello, et al.
Publicado: (2021)

A two-year longitudinal study of retinal vascular impairment in patients with amnestic mild cognitive impairment
por: Criscuolo, Chiara, et al.
Publicado: (2022)

Corrigendum: A two-year longitudinal study of retinal vascular impairment in patients with amnestic mild cognitive impairment
por: Criscuolo, Chiara, et al.
Publicado: (2023)

Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis
por: Carotenuto, Antonio, et al.
Publicado: (2021)

Determinants of early working impairments in multiple sclerosis
por: Moccia, Marcello, et al.
Publicado: (2022)

Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study
por: Scotto, Riccardo, et al.
Publicado: (2023)

Pneumocystis jirovecii pneumonia in COVID-19: an overlooked clinical entity—Response to “Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19”
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2021)

A Retrospective Exploratory Analysis on Cardiovascular Risk and Cognitive Dysfunction in Multiple Sclerosis
por: Reia, Antonio, et al.
Publicado: (2021)

Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge
por: Scotto, Riccardo, et al.
Publicado: (2022)

Multiple Sclerosis in the Campania Region (South Italy): Algorithm Validation and 2015–2017 Prevalence
por: Moccia, Marcello, et al.
Publicado: (2020)

Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens
por: Zappulo, Emanuela, et al.
Publicado: (2019)

Impact of COVID-19 and system recovery in delivering healthcare to people with multiple sclerosis: a population-based Study
por: Affinito, Giuseppina, et al.
Publicado: (2023)

Social Media and Multiple Sclerosis in the Posttruth Age
por: Lavorgna, Luigi, et al.
Publicado: (2017)

Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials
por: Moccia, Marcello, et al.
Publicado: (2020)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
por: Gentile, Ivan, et al.
Publicado: (2022)

Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience
por: Rosa, Laura, et al.
Publicado: (2022)

Retinal and Choriocapillary Vascular Changes in Early Stages of Multiple Sclerosis: A Prospective Study
por: Montorio, Daniela, et al.
Publicado: (2021)

Voxel-based analysis of gray matter relaxation rates shows different correlation patterns for cognitive impairment and physical disability in relapsing-remitting multiple sclerosis
por: Cassiano, Maria Teresa, et al.
Publicado: (2020)

Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis
por: Moccia, Marcello, et al.
Publicado: (2019)

JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level
por: Lanzillo, Roberta, et al.
Publicado: (2014)

Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
por: Gentile, Ivan, et al.
Publicado: (2021)

Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis
por: Novarella, Federica, et al.
Publicado: (2022)

Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis
por: Cennamo, Gilda, et al.
Publicado: (2020)

Internal Jugular Vein Blood Flow in Multiple Sclerosis Patients and Matched Controls
por: Mancini, Marcello, et al.
Publicado: (2014)

Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
por: Capasso, Nicola, et al.
Publicado: (2022)

Radial peripapillary vessel density as early biomarker in preperimetric glaucoma and amnestic mild cognitive impairment
por: Montorio, Daniela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hm7229sd4kufl57m1r7hl2ntne